Skip to main content

Table 1 Patient demographics

From: Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series

Patient Skeletal AE Age Sex Race BMI Tumor type and stage Treatment Regimen Bone Metastases? Other irAEs
1 Compression fractures of T6, T7, T10, T11, and T12; rib and pelvic fractures 75 M C 19 Melanoma
Stage IV
Pembrolizumab No None
2 Compression fractures, T6–12, L1 52 M C 27 Melanoma
Stage IV
Nivolumab Yes None
3 Compression fracture, T11; lumbar osteomalacia 58 M C 29 Melanoma
Stage IV
Pembrolizumab No None
4 Resorptive bone lesion, left shoulder 60 M C 24 Melanoma
Stage IV
Ipilimumab/nivolumab No Pneumonitis, hypophysitis, inflammatory arthritis
5 Resorptive bone lesion, right wrist 60 F C 26 Renal cell carcinoma
Stage IV
Nivolumab Yes Inflammatory arthritis
6 Resorptive bone lesion, right clavicle 51 M C 25 Non small cell lung cancer
Stage II
Ipilimumab/nivolumab Yes Inflammatory arthritis
  1. (AE) Adverse event, (irAEs) Immune-related adverse events